Patrick Burnett, MD, PhD, of Arcutis, explores new treatments for vitiligo and hidradenitis suppurativa, while advancing systemic biologics for atopic dermatitis by 2026.
Patrick Burnett, MD, PhD
Advertisement
Patrick Burnett, MD, PhD, is a board-certified dermatologist and the chief medical officer of Arcutis Biotherapeutics.
Articles by Patrick Burnett, MD, PhD
Arcutis is advancing pediatric dermatology with innovative, steroid-sparing treatments for atopic dermatitis and plaque psoriasis, enhancing care for young patients.
Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.
The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.
Advertisement
Latest Updated Articles
Patrick Burnett, MD, PhD, Highlights Arcutis’ New Seborrheic Dermatitis Initiative With Odell Beckham Jr.Published: February 17th 2025 | Updated:
Patrick Burnett, MD, PhD, Outlines Arcutis' Pediatric Strategy for Roflumilast in AD and PsoriasisPublished: December 1st 2025 | Updated:
Pipeline Updates on the Horizon From Arcutis BiotherapeuticsPublished: March 6th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
